Who is sponsoring NCT04385836?

NCT04385836 is sponsored by Ministry of Health, Saudi Arabia.

What drugs are being tested in NCT04385836?

Interventions in NCT04385836: alpha one antitrypsin inhalation.

What condition does NCT04385836 study?

NCT04385836 studies Coronavirus.

Is NCT04385836 still recruiting?

NCT04385836 is currently status unknown. Last updated 13 May 2020.

Last reviewed 2020-05-13 · How we verify

NCT04385836

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Status unknown EARLY_PHASE1 Last updated 13 May 2020

What this trial tests

EARLY_PHASE1 trial testing alpha one antitrypsin inhalation in Coronavirus in 150 participants. Status unknown.

Timeline

1 June 2020

Primary endpoint
1 September 2020

1 September 2020

Quick facts

Lead sponsor	Ministry of Health, Saudi Arabia
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	150
Start date	1 June 2020
Primary completion	1 September 2020
Estimated completion	1 September 2020
Sites	1 location across Saudi Arabia

Drugs / interventions tested

alpha one antitrypsin inhalation — full drug profile →

Conditions studied

Coronavirus — all drugs for Coronavirus →

Sponsor

Ministry of Health, Saudi Arabia

Who can join

18 and older, any sex, with Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV Transmembrane protease serine type 2 (TMPRSS2), a protease belonging to the type II transmembrane serine protease family, cleaves the coronavirus spike protein Serine proteases are inhibited by a diverse group of inhibitors, The best-studied serpins are antithrombin and alpha 1-antitrypsin

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.
Wettstein L, Weil T, Conzelmann C, Müller JA, et al · · 2021 · cited 114× · PMID 33741941 · DOI 10.1038/s41467-021-21972-0
A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases.
He S, Gui J, Xiong K, Chen M, et al · · 2022 · cited 91× · PMID 35241085 · DOI 10.1186/s12951-022-01307-x
SARS-CoV-2 Antiviral Therapy.
Tao K, Tzou PL, Nouhin J, Bonilla H, et al · · 2021 · cited 80× · PMID 34319150 · DOI 10.1128/cmr.00109-21
Neutrophils in COVID-19: Not Innocent Bystanders.
McKenna E, Wubben R, Isaza-Correa JM, Melo AM, et al · · 2022 · cited 76× · PMID 35720378 · DOI 10.3389/fimmu.2022.864387
Aprotinin Inhibits SARS-CoV-2 Replication.
Bojkova D, Bechtel M, McLaughlin KM, McGreig JE, et al · · 2020 · cited 61× · PMID 33143316 · DOI 10.3390/cells9112377
A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application.
O'Brien ME, Murray G, Gogoi D, Yusuf A, et al · · 2022 · cited 57× · PMID 35269582 · DOI 10.3390/ijms23052441
The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.
Wettstein L, Kirchhoff F, Münch J. · · 2022 · cited 55× · PMID 35163273 · DOI 10.3390/ijms23031351
Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza.
Cambier S, Metzemaekers M, de Carvalho AC, Nooyens A, et al · · 2022 · cited 50× · PMID 34793331 · DOI 10.1172/jci.insight.155055

Verify or expand the search:

Other recruiting trials for Coronavirus

Currently open trials in the same condition.

NCT04772170 — Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies · recruiting
NCT05868239 — Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study · NA · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting

Other Ministry of Health, Saudi Arabia trials

Trials by the same sponsor.

NCT06057077 — Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus · Phase 1, PHASE2 · unknown
NCT05957939 — Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial · Phase 1 · unknown
NCT06026163 — Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress · Phase 2, PHASE3 · recruiting
NCT06071338 — A Decision Support System Based on Classification Algorithms for the Diagnosis of Periodontal Disease · unknown
NCT05680662 — The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Can · EARLY_PHASE1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04385836 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ministry of Health, Saudi Arabia
Last refreshed: 13 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04385836.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing